Revenue growth reached 22.0% in 2026Q1, yet the company continues to struggle with profitability as SG&A expenses consume the entirety of its 68.0% gross margin.
| Sales/Revenue | 81.18M | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M | 28.4M | 25.36M |
| Revenue Growth % | 20.85% | 18.56% | 4.49% | 31.14% | 17.58% | 42.43% | 11.98% | - |
| Cost of Goods Sold | 26.56M | 29.46M | 21.24M | 19.46M | 16.31M | 15.23M | 10.71M | 7.53M |
| COGS % of Revenue | - | 38.12% | 32.58% | 31.2% | 34.29% | 37.65% | 37.71% | 29.7% |
| Gross Profit | 54.62M | 47.81M | 43.94M | 42.91M | 31.25M | 25.22M | 17.69M | 17.83M |
| Gross Margin % | 67.28% | 61.88% | 67.42% | 68.8% | 65.71% | 62.35% | 62.29% | 70.3% |
| Gross Profit Growth % | - | 8.82% | 2.39% | 37.3% | 23.92% | 42.56% | -0.78% | - |
| Operating Expenses | 126.37M | 118.74M | 110.5M | 117.74M | 119.08M | 96.71M | 55.08M | 50.12M |
| OpEx % of Revenue | - | 153.67% | 169.56% | 188.77% | 250.37% | 239.09% | 193.94% | 197.61% |
| Selling, General & Admin | 91.67M | 85.17M | 76.32M | 81.72M | 84.08M | 70.24M | 36.4M | 35.08M |
| SG&A % of Revenue | - | 110.23% | 117.11% | 131.03% | 176.79% | 173.65% | 128.16% | 138.33% |
| Research & Development | 35.89M | 33.57M | 34.37M | 36.97M | 35.37M | 26.58M | 18.59M | 15.02M |
| R&D % of Revenue | - | 43.44% | 52.73% | 59.27% | 74.37% | 65.71% | 65.45% | 59.21% |
| Other Operating Expenses | -1000K | 0 | -183K | -954K | -377K | -108K | 93K | 16K |
| Operating Income | -71.75M | -70.92M | -66.57M | -74.83M | -87.82M | -71.49M | -37.39M | -32.29M |
| Operating Margin % | -88.39% | -91.79% | -102.14% | -119.97% | -184.66% | -176.73% | -131.64% | -127.3% |
| Operating Income Growth % | - | -6.55% | 11.04% | 14.8% | -22.85% | -91.21% | -15.8% | - |
| EBITDA | -63.1M | -61.4M | -57.97M | -66.49M | -82.25M | -67.88M | -35M | -30.37M |
| EBITDA Margin % | -77.73% | -79.46% | -88.95% | -106.6% | -172.94% | -167.81% | -123.23% | -119.76% |
| EBITDA Growth % | -14.69% | -5.91% | 12.81% | 19.16% | -21.17% | -93.96% | -15.22% | - |
| D&A (Non-Cash Add-back) | 8.65M | 9.53M | 8.6M | 8.34M | 5.57M | 3.61M | 2.39M | 1.91M |
| EBIT | -74.76M | -70.92M | -59.36M | -77.91M | -86.95M | -72.85M | -40.38M | -32.65M |
| Net Interest Income | -3.85M | -2.68M | 1.45M | 3.96M | 685K | -638K | -744K | -890K |
| Interest Income | 1.09M | 1.87M | 3.36M | 4.55M | 1.32M | 20K | 96K | 86K |
| Interest Expense | 4.94M | 4.55M | 1.91M | 588K | 639K | 658K | 840K | 976K |
| Other Income/Expense | -7.92M | -7.56M | 5.3M | -3.67M | 238K | -2.02M | -3.84M | -1.34M |
| Pretax Income | -79.67M | -78.49M | -61.27M | -78.5M | -87.58M | -73.51M | -41.23M | -33.63M |
| Pretax Margin % | -98.14% | -101.57% | -94.01% | -125.85% | -184.16% | -181.72% | -145.16% | -132.6% |
| Income Tax | 1.26M | 512K | 1.22M | 486K | -136K | 168K | -1.89M | 162K |
| Effective Tax Rate % | -1.58% | -0.65% | -2% | -0.62% | 0.16% | -0.23% | 4.57% | -0.48% |
| Net Income | -80.94M | -79M | -62.49M | -78.98M | -87.45M | -73.67M | -39.34M | -33.79M |
| Net Margin % | -99.7% | -102.24% | -95.89% | -126.63% | -183.87% | -182.14% | -138.52% | -133.23% |
| Net Income Growth % | -22.31% | -26.41% | 20.88% | 9.68% | -18.7% | -87.28% | -16.42% | - |
| Net Income (Continuing) | -80.94M | -79M | -62.49M | -78.98M | -87.45M | -73.67M | -39.34M | -33.79M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.14 | -1.17 | -0.95 | -1.22 | -1.36 | -1.33 | -0.82 | -0.53 |
| EPS Growth % | -18% | -23.16% | 22.13% | 10.29% | -2.26% | -62.2% | -54.72% | - |
| EPS (Basic) | - | -1.17 | -0.95 | -1.22 | -1.36 | -1.33 | -0.82 | -0.53 |
| Diluted Shares Outstanding | 71.14M | 67.54M | 65.78M | 64.75M | 64.1M | 55.3M | 48.02M | 63.86M |
| Basic Shares Outstanding | 71.14M | 67.54M | 65.78M | 64.75M | 64.1M | 55.3M | 48.02M | 63.86M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Insufficient liquidity for operations
According to recent financial disclosures, SOPH achieved a 22.0% year-over-year revenue growth in 2026Q1, signaling a consistent recovery from the contraction observed in 2024Q3 and suggesting that the company's platform-agnostic diagnostic model is successfully capturing increased clinical volume across its global network of hospital partners.
The acceleration in top-line performance appears to be driven by the successful scaling of the DDM platform, which benefits from a recurring-like consumption model. Investors should monitor whether this growth trajectory can be sustained without a proportional increase in customer acquisition costs, as the company attempts to reach critical mass.
As reported in quarterly filings, SOPH maintained a gross margin of 68.0% in 2026Q1, demonstrating that the company's software-centric architecture effectively manages the variable costs associated with genomic data processing despite the inherent volatility of cloud-based infrastructure expenses required for large-scale diagnostic analysis.
The stability of these margins suggests that the company possesses a degree of pricing power or operational efficiency in its core informatics offering. However, the inability to translate this gross profitability into positive operating income indicates that the current cost structure remains heavily burdened by non-production overhead.
Based on the provided income statements, SOPH's operating margin of -79.7% in 2026Q1 highlights a persistent failure to achieve operating leverage, as SG&A expenses continue to consume the entirety of gross profit, leaving the firm reliant on external capital to fund its ongoing research and development initiatives.
The lack of meaningful improvement in operating margins suggests that the company's growth strategy is currently prioritizing market share over immediate profitability. This warrants further investigation into whether the current SG&A spend is truly scalable or if it represents a structural inefficiency that will continue to weigh on earnings.
Data from recent filings indicates that SOPH faces a precarious financial position, with a TTM operating loss of approximately $70.9M against a cash balance of only $70.3M, suggesting that the company may face significant financing risks if it cannot rapidly improve its cash flow profile.
Short-term investors should be wary of the potential for dilutive capital raises, which appear increasingly likely given the current burn rate. The reliance on external funding to sustain operations creates a binary risk profile where any delay in achieving operational self-sufficiency could severely impact shareholder value.
Quick answers to the most common questions about buying SOPH stock.
For fiscal year 2025, SOPHiA GENETICS S.A. (SOPH) reported total revenue of $77.3M. This represents a 204.7% increase compared to $25.4M in 2019.
SOPHiA GENETICS S.A. (SOPH) reported a net loss of $79.0M for the fiscal year ending 2025.
SOPHiA GENETICS S.A. (SOPH) reported an operating income of $-70.9M, resulting in an operating profit margin of -91.8%. This margin reflects the operational efficiency of the business before interest and taxes.
SOPHiA GENETICS S.A. (SOPH) generated $47.8M in gross profit for the year, representing a gross profit margin of 61.9%. This demonstrates the company's core pricing power and production efficiency.